5 Most Promising Gene Editing Stocks According to Analysts

2. Intellia Therapeutics, Inc. (NASDAQ:NTLA

Number of Hedge Fund Holders: 39

One-Year Average Price Target: $96.28

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the most notable gene editing companies working on CRISPR-based technologies.

Earlier this month, the US FDA cleared Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s application seeking to start a trial of CRISPR-based gene editing therapy NTLA-2002 in the U.S. to treat hereditary angioedema (HAE).

At the end of the fourth quarter of 2022, 39 hedge funds out of the 943 funds tracked by Insider Monkey reported owning stakes in Intellia Therapeutics, Inc. (NASDAQ:NTLA). The total value of these stakes at the end of the quarter was $690 million. The biggest stakeholder of Intellia Therapeutics, Inc. (NASDAQ:NTLA) was ARK Investment Management which had a $328 million stake in the company.